Overview

• A Pro Generika–commissioned study examined 56 supply‑relevant active ingredients and found 20 where Chinese dominance means a halt would endanger German medicine supply.
• Antibiotics, diabetes treatments and common painkillers are flagged as most exposed, with the report saying short‑term substitution is technically not feasible.
• The study’s stress test estimates 42 million pack units annually would be unavailable if Chinese producers stopped deliveries.
• Asia supplies 68% of APIs for Europe—24% from China and 37% from India—while Europe accounts for only 23% of antibiotic production sites.
• Authors warn China could use export restrictions as leverage, and industry leaders urge policies to secure production and diversify sourcing, with no new government actions detailed.